Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection.
about
Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complexMechanism for neutralizing activity by the anti-CMV gH/gL monoclonal antibody MSL-109A derivative of platelet-derived growth factor receptor alpha binds to the trimer of human cytomegalovirus and inhibits entry into fibroblasts and endothelial cellsPreexisting antibodies can protect against congenital cytomegalovirus infection in monkeys.Soluble Human Cytomegalovirus gH/gL/pUL128-131 Pentameric Complex, but Not gH/gL, Inhibits Viral Entry to Epithelial Cells and Presents Dominant Native Neutralizing EpitopesPhase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy Adults.Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin.Cytomegalovirus seropositivity is associated with glucose regulation in the oldest old. Results from the Leiden 85-plus Study.A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells.A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques.Vaccination with synthetic constructs expressing cytomegalovirus immunogens is highly T cell immunogenic in mice.A First-in-Human Study To Assess the Safety and Pharmacokinetics of Monoclonal Antibodies against Human Cytomegalovirus in Healthy VolunteersIn Vitro Characterization of Human Cytomegalovirus-Targeting Therapeutic Monoclonal Antibodies LJP538 and LJP539.Antibody inhibition of human cytomegalovirus spread in epithelial cell culturesPreclinical evaluations of peptide-conjugate vaccines targeting the antigenic domain-2 of glycoprotein B of human cytomegalovirus.Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine.Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activityNeutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex.The history of vaccination against cytomegalovirus.Complex correlates of protection after vaccination.Impact of Antibodies and Strain Polymorphisms on Cytomegalovirus Entry and Spread in Fibroblasts and Epithelial Cells.A two-step screening approach for the identification of blood donors with highly and broadly neutralizing capacities against human cytomegalovirus.Maternal Antibody Responses and Nonprimary Congenital Cytomegalovirus Infection of HIV-1-Exposed Infants.A replication-defective human cytomegalovirus vaccine for prevention of congenital infection.Persistent Cytomegalovirus Infection in Amniotic Membranes of the Human Placenta.Early high CMV seroprevalence in pregnant women from a population with a high rate of congenital infection.Active evolution of memory B-cells specific to viral gH/gL/pUL128/130/131 pentameric complex in healthy subjects with silent human cytomegalovirus infection.Human cytomegalovirus vaccine development: Immune responses to look into vaccine strategy.Human Macrophages Escape Inhibition of Major Histocompatibility Complex-Dependent Antigen Presentation by Cytomegalovirus and Drive Proliferation and Activation of Memory CD4+ and CD8+ T Cells.Large-Scale Screening of HCMV-Seropositive Blood Donors Indicates that HCMV Effectively Escapes from Antibodies by Cell-Associated Spread
P2860
Q21089588-2D8DFF75-DE6C-4004-8FB3-871EFDC1CA39Q27683850-2CE62CA9-8A16-4A2B-B842-CEF0EE7CD436Q33558900-C7865419-935F-4BDB-9E7C-9054A86FC23CQ33877783-E88D8D84-69E1-4B36-A17A-82ABDCF9E43AQ35783065-1BE968CC-551C-4BD4-8FCB-3B581B3A7C1CQ35859879-02C41F4F-9D03-4680-903B-C5C52C635739Q36155456-E70D040D-7091-4CA4-89B6-70A1272825C2Q36341023-7EAA8258-4A7E-4D98-B9A9-7531E1DABF44Q36385141-A5AF16E5-3667-4F09-88C3-2CE5585224FCQ36559845-D62E2FF8-E0BB-4D85-90C5-E2B01941AC69Q36694861-2B136083-5A47-4B7C-8952-BF3D76EBE5B9Q36888046-8CF785EB-246C-4D58-B3C2-31EC0EC71552Q37120061-A188F215-8BF9-4C63-8FC3-2CD608930B48Q37174327-22E43A7A-F2F5-42D2-8AE0-4C0FF63CBC47Q37197051-642A4FB5-12F4-4B75-AC66-E30EE14904DCQ37409489-0DE7701E-D995-4268-B0A8-9EAC7A74B0F6Q37545058-CCF725E8-1005-4B51-A17B-76E0DB73F335Q37707461-7CBDF4A7-2620-443D-9079-F6174517D46FQ38384533-057F40DC-47A7-45D4-9F73-F12EB6DA939AQ38456515-34442E99-B7DB-401E-90A7-B1A82BD7B307Q38708710-DB3AEEB7-9A5E-4728-BEB5-EA967CBAF4D6Q38730422-7FA15B8C-67CC-4B15-86B8-0C8146F0DF47Q38908361-0094C314-27C3-407D-8E8A-EBD7CFC6E824Q40474474-C7DE1DF7-52FA-4EF2-8761-90F7D1E3CD84Q40480154-F14B3AC7-2D54-432F-A2AF-9D65A0EFA41FQ42284386-5137B3F8-4C1E-4BEB-B775-F33135EF7771Q47135919-8B65793F-E086-4A63-ABCA-1B1C8381D100Q47605886-A81BF249-F637-43D5-8AFC-D87E36824BFDQ55401180-1DE2EB62-911E-4D76-9F9E-8EDBD9684BB5Q58738833-A5269E34-A41A-4FB1-AB49-BBAB807F7027
P2860
Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Quantitative analysis of neutr ...... alovirus in natural infection.
@en
Quantitative analysis of neutr ...... alovirus in natural infection.
@nl
type
label
Quantitative analysis of neutr ...... alovirus in natural infection.
@en
Quantitative analysis of neutr ...... alovirus in natural infection.
@nl
prefLabel
Quantitative analysis of neutr ...... alovirus in natural infection.
@en
Quantitative analysis of neutr ...... alovirus in natural infection.
@nl
P2093
P1433
P1476
Quantitative analysis of neutr ...... galovirus in natural infection
@en
P2093
Aimin Tang
Daniel C Freed
Danilo R Casimiro
Fengsheng Li
Shannon N Grimes
Tong-Ming Fu
P304
P356
10.1016/J.VACCINE.2011.09.056
P407
P577
2011-09-22T00:00:00Z